Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

2.120 +0.010 (+0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
From Repare Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet ↗
 
Via Benzinga
News headline image
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast ↗
 
Via Benzinga
News headline image
Why Is Repare Therapeutics Stock Trading Lower On Friday? ↗
Repare Therapeutics shares MYTHIC trial data, highlighting Lunre+Camo's tolerability and efficacy in gynecologic cancers with FDA guidance on next steps. 
Via Benzinga
News headline image
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus ↗
U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher. 
Via Benzinga
Topics Economy
News headline image
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.